Information Provided By: 
Fly News Breaks for November 12, 2018
TNDM, PODD, DXCM
Nov 12, 2018 | 05:21 EDT
Piper Jaffray analyst JP McKim left this weekend's Diabetes Technology Meeting feeling that DexCom (DXCM) "has a lot in its pipeline" and remains a few steps ahead of the competition, Insulet (PODD) is having "great success" in the pharmacy and is on the forefront of cybersecurity, and Tandem Diabetes (TNDM) remains in a "strong position to take market share." The analyst continues to like pure play diabetes names and keeps an Overweight rating on all three names.
News For DXCM;PODD;TNDM From the Last 2 Days
DXCM
Apr 26, 2024 | 12:03 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 26, 2024 | 09:14 EDT
DXCM
Apr 26, 2024 | 07:45 EDT
Canaccord analyst William Plovanic raised the firm's price target on DexCom to $145 from $144 and keeps a Buy rating on the shares. The firm said they reported a slight;ly better than expected Q1 as the company raised the low-end and mid-point of its revenue guidance and reiterated its adjusted GM/OM/EBITDA margins for 2024.
DXCM
Apr 25, 2024 | 17:21 EDT
Check out this evening's top movers from around Wall Street, compiled by The Fly. HIGHER AFTER EARNINGSSnap (SNAP) up... To see the rest of the story go to thefly.com. See Story Here
DXCM
Apr 25, 2024 | 16:05 EDT
DXCM
Apr 25, 2024 | 16:04 EDT
DXCM
Apr 25, 2024 | 15:11 EDT
Pre-earnings options volume in DexCom is 11.4x normal with calls leading puts 11:2. Implied volatility suggests the market is anticipating a move near 5.8%, or $8.05, after results are released. Median move over the past eight quarters is 5.4%.
DXCM
Apr 25, 2024 | 13:09 EDT
TNDM
Apr 25, 2024 | 06:13 EDT
TNDM
Apr 25, 2024 | 06:02 EDT
Leerink upgraded Tandem Diabetes to Outperform from Market Perform with a $45 price target.
